Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region

Antimicrob Agents Chemother. 1997 Jun;41(6):1380-4. doi: 10.1128/AAC.41.6.1380.

Abstract

Pseudomonas aeruginosa isolates from 1 of 17 cystic fibrosis patients produced secondary beta-lactamase in addition to the ampC beta-lactamase. Isolates were grouped into three beta-lactamase expression phenotypes: (i) beta-lactam sensitive, low basal levels and inducible beta-lactamase production; (ii) beta-lactam resistant, moderate basal levels and hyperinducible beta-lactamase production; (iii) beta-lactam resistant, high basal levels and constitutive beta-lactamase production. Apart from a base substitution in the ampR-ampC intergenic region of an isolate with moderate-basal-level and hyperinducible beta-lactamase production, sensitive and resistant strains were identical in their ampC-ampR genetic regions. Thus, enhanced beta-lactamase expression is due to mutations in regulatory proteins other than AmpR.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chronic Disease
  • Cystic Fibrosis / microbiology*
  • DNA, Bacterial / genetics
  • Gene Amplification
  • Genes, Bacterial*
  • Humans
  • Mutation
  • Phenotype
  • Plasmids
  • Promoter Regions, Genetic
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / enzymology*
  • Pseudomonas aeruginosa / genetics*
  • Restriction Mapping
  • beta-Lactam Resistance
  • beta-Lactamases / genetics*
  • beta-Lactamases / metabolism*

Substances

  • DNA, Bacterial
  • beta-Lactamases